Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Antitrust Pressure On J&J Grows As Walgreen, Kroger Sue Over Remicade Contracts

Executive Summary

Pharmacy chains object to J&J agreements with insurers that block coverage of Pfizer and Merck biosimilars except in 'rarest of circumstances'; seek overcharge damages for Remicade purchases.

You may also be interested in...



Pointing Fingers On Biosimilars: FDA Versus FTC

US FDA is talking tough on antitrust enforcement. But is there any reason to think FTC is listening?

Pointing Fingers On Biosimilars: FDA Versus FTC

US FDA is talking tough on antitrust enforcement. But is there any reason to think FTC is listening?

Biosimilar Substitution: US State Laws Require Physician Communication And, In Some Cases, Lower Prices

Bills allowing pharmacies to substitute biosimilars for reference biologics have been enacted in all but six states. Interactive map notes state-by-state provisions.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS123257

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel